Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1

Bai,Zhigang; Zhang,Zhongtao; Qu,Xiang; Han,Wei; Ma,Xuemei

doi:10.3892/ol.2011.416

January 2012 Volume 3 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January 2012 Volume 3 Issue 1

Full Size Image

Article

Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1

Authors:
- Zhigang Bai
- Zhongtao Zhang
- Xiang Qu
- Wei Han
- Xuemei Ma
View Affiliations / Copyright

Affiliations: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Pages: 135-140
|
Published online on: September 9, 2011

https://doi.org/10.3892/ol.2011.416
Expand metrics +

Abstract

The purpose of this study was to determine the role of taxol resistance gene 1 (TXR1) in a taxol-resistant breast cancer cell line. Expression levels of TXR1 and thrombospondin-1 (TSP1) were detected by RT-PCR and Western blot analysis. In MCF-7 cells transfected with TXR1 plasmids, the expression of a number of drug resistance genes was monitored, as well as cell proliferation. MCF-7 cells were also transiently transfected with a chemically synthesized small interfering RNA (siRNA) targeting TXR1. Taxol concentrations varying from 0.6 to 6 µg/ml were shown to inhibit the proliferation of MCF-7 cells in a time- and dose-dependent manner by arresting cells in the G2/M phase. Additionally, 0.06 µg/ml taxol was used to establish a taxol-resistant MCF-7 cell line, MCF-7/T. When TXR1 was exogenously expressed, a taxol-resistant phenotype was further induced and the expression levels of BCRP, GSTP1 and MVP increased. Transient transfection of TXR1-targeting siRNAs was shown to restore the chemosensitivity of MCF-7 cells. These results suggest that an increased expression of TXR1 is a novel mechanism for reversing the taxol resistance of breast cancer cells.

View Figures

View References

1	Marsh S and McLeod HL: Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 8:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
2	Moore A: Breast-cancer therapy-looking back to the future. N Engl J Med. 357:1547–1549. 2007. View Article : Google Scholar
3	Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci. 13:134–136. 1992. View Article : Google Scholar
4	Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl J Med. 358:1663–1671. 2008. View Article : Google Scholar : PubMed/NCBI
5	Broxterman HJ, Gotink KJ and Verheul HM: Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 12:114–126. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sangrajrang S and Fellous A: Taxol resistance. Chemotherapy. 46:327–334. 2000. View Article : Google Scholar
7	Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA and Horwitz SB: Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 63:1207–1213. 2003.PubMed/NCBI
8	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
9	Ferguson T, Wilcken N, Vagg R, Ghersi D and Nowak AK: Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 17:CD0044212007.PubMed/NCBI
10	Kutuk O and Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 68:7985–7994. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hudis C and Dang C: The taxane limbo: how low can we go? J Natl Cancer Inst. 100:761–763. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lih CJ, Wei W and Cohen SN: Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 20:2082–2095. 2006. View Article : Google Scholar : PubMed/NCBI
13	Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP and Polverini PJ: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res. 37:209–218. 2000. View Article : Google Scholar : PubMed/NCBI
14	Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V and Souglakos J: Tumoral Expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res. 15:3827–3833. 2009. View Article : Google Scholar : PubMed/NCBI
15	Greenberger LM, Lothstein L, Williams SS and Horwitz SB: Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA. 85:3762–3766. 1988. View Article : Google Scholar : PubMed/NCBI
16	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
17	Van Amerongen R and Berns A: TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev. 20:1975–1981. 2006.PubMed/NCBI
18	Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of taxol resistance related to microtubules. Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM and Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep. 5:249–255. 1998.PubMed/NCBI
20	McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
21	Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE and Cabot MC: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem. 272:1682–1687. 1997. View Article : Google Scholar
22	Longley D and Johnston P: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar